Ocuphire Pharma Investor Updates

P 21 Secondary Endpoint: Safety Findings Nyxol+LDP Combination Was Well Tolerated With A Favorable Safety Profile In VEGA-1 Trial Total Treatment Emergent Adverse Events (n) TEAES by Severity (n [%]) Mild Moderate Severe AES Occurring in ≥ 5% of subjects (n [%]) Instillation Site Pain (Mild) Instillation Site Erythema (Mild) Conjunctival Hyperemia (Mild) Eye Disorders (Mild) Placebo Alone Nyxol Alone n=45 n=30 4 1 (2.2%) 1 (2.2%) 0 (0%) 1 (2.2%) 0 (0%) 0 (0%) 1 (2.2%) 18 6 (20%) 0 (0%) 0 (0%) 3 (10%) 3 (10%) 2 (6.7%) 2 (6.7%) LDP Alone n=31 13 6 (19.4%) 0 (0%) 0 (0%) 0 (0%) 2 (6.5%) 0 (0%) 4 (12.9%) Nyxol+LDP n=44 50 13 (29.5%) 1 (2.3%) 1 (2.3%) 4 (9.1%) 5 (11.4%) 2 (4.5%) 5 (11.4%) Source: VEGA-1 TLR Table 14.3.1.1 Overall Summary of Treatment Emergent Adverse Events (TEAE) (Safety Population) Table 14.3.1.3 Treatment-Emergent Adverse Events (TEAE) by System Organ Class, Preferred Term, and Severity (Safety Population) ● ● ● No deaths, no serious AEs, and 1 withdrawal due to AEs (on Nyxol alone) 0% Headaches or Browaches reported for Nyxol+LDP and Nyxol alone Only 1 subject in LDP alone arm reported mild headache Almost all AEs were mild and most common was mild instillation site discomfort Distance visual acuity not adversely affected (as shown earlier) No change in IOP Ocuphire PHARMA

View entire presentation